
Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its earning forecasts again as it unveiled a new chief executive to tackle "recent market challenges".
The downward revisions prompted heavy selling by investors on the Copenhagen stock exchange, with Novo shares plunging 22 percent in afternoon trading.